Company announcement

PME signs Research Collaboration agreement with NYU Langone Health

11 September 2020

HIGHLIGHTS

- **PME signs multi-year Research Collaboration agreement with NYU Langone Health**
- **PME and NYU Langone to jointly develop next-generation enterprise imaging solutions**
- **PME to establish Research/R&D Hub in New York City**
- **New Hub to form the foundation for Visage research activities in the U.S.**
- **Significant investment in future PME products**

Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has signed a multi-year Research Collaboration agreement with NYU Langone Health (NYU Langone), one of the most highly regarded health systems in North America.

Under the terms of the agreement, the two parties will work together to design and develop next-generation products for enterprise imaging in areas such as workflow optimization, integration with multi-vendor reporting platforms, as well as integration of artificial intelligence (AI) technology. NYU Langone will also become a member of the Visage AI Accelerator program.

"This is a major milestone for our company," said Dr Sam Hupert, Pro Medicus CEO. "We changed the paradigm of what a diagnostic imaging (PACS) product should be by natively integrating 3D and advanced visualisation into a single platform. We believe this, combined with our proprietary streaming platform, has given us an 18 to 24 month technology lead. We are now looking at what is next, what a system would look like in say 3 to 5 years, and are starting to do the research and development to make that a reality and then be the first to commercialise it."

In addition to working on-premise at NYU Langone, PME will establish its own R&D Hub in New York City to spearhead PME's research and commercialization opportunities in the U.S.

"Having our own R&D presence in North America will enable us to leverage the development and commercialisation potential of our Visage AI Accelerator and other programs across our rapidly increasing base of North America's top academic, research-oriented clients. We see this as a significant investment in our future, one that will provide us with a strategic advantage in the rapidly evolving fields of enterprise imaging and AI."

"We are excited to collaborate with Visage in the areas of image viewing, workflow optimization and the incorporation of artificial intelligence into the daily workflow of radiologists," said Dr Michael Recht, the Louis Marix Professor and Chair of Radiology at NYU Langone. "The integration of Visage's development team, and NYU Langone radiologists and imaging scientists, will create a unique synergy and the potential for significant advances in these areas."

Authorised by the Board of Pro Medicus Limited.

For further information:

Dr Sam Hupert
Chief Executive Officer
Pro Medicus Limited
Ph: +61 3 9429 8800

Media:

Richard Allen
Oxygen Financial Public Relations
Ph: +61 3 9915 6341

About Pro Medicus Limited:

Pro Medicus Limited [ASX: PME] is a leading medical imaging IT provider. Founded in 1983, the company provides a full range of radiology IT software and services to hospitals, imaging centres and health care groups worldwide. In late January 2009, the company announced the purchase of Visage Imaging, which has become a global provider of leading edge enterprise imaging solutions, pioneering the best-of-breed, or Deconstructed PACS® enterprise imaging strategy. Visage 7 technology delivers amazingly fast, multi-dimensional images streamed via an intelligent thin-client viewer. The company offers a leading suite of RIS, PACS and e-health solutions constituting one of the most comprehensive end-to-end offerings in radiology. Pro Medicus has global offices in Melbourne, Berlin and San Diego. www.promed.com.au